ArticleArchives of microbiology2026
A novel jumbo phage infecting Pseudomonas aeruginosa: genomic insights and phylogenetic classification.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Bacteriophages have re-emerged as therapeutic alternatives to antibiotics, and jumbo phages, are of particular interest due to their unique genetic features. In this study, a novel jumbo bacteriophage, vB_Pae_HU_K1-1, with lytic activity against P. aeruginosa, was isolated from wastewater. Its genome was sequenced and annotated, followed by phylogenetic classification and comparative genomic analyses. The phage’s biological and morphological characteristics were determined using STEM, MOI analysis, and one-step growth curve assays. The cytotoxicity of the phage were evaluated on the HaCaT cells via the MTT test, while its antibiofilm efficacy was assessed using the CV staining. Additionally, homology modelling analyses were conducted for genes encoding lysin, chimallin, and tubulin-like proteins. vB_Pae_HU_K1-1 has a 281,858 bp genome containing 371 CDS. Genome analysis revealed that it belongs to the family Chimalliviridae. However, its intergenomic similarity to the genus Noxifervirus, which showed the highest similarity, was below 70%, suggesting that the phage may represent a novel genus. Homology modelling of chimallin and tubulin-like proteins further supported this classification. Additionally, AcaFinder identified four high-confidence Acr candidates in the vB_Pae_HU_K1-1 genome. In-vitro tests demonstrated that the phage had no cytotoxic effect on HaCaT cells, and biofilm analyses showed that it significantly inhibited P. aeruginosa biofilm formation (p = 0.01). vB_Pae_HU_K1-1 appears to represent a potential new genus within Chimalliviridae, distinguished by its genetic structure and functional characteristics. Its antibiofilm activity and in vitro biocompatibility highlight its potential for future therapeutic and biotechnological research, while contributing to our understanding of the diversity and functional capacity of jumbo phages.
Indexed as
Identifiers
42029752What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.